Metformin improves skin flap survival through nitric oxide system

Area of Science:

• Regenerative Medicine
• Pharmacology
• Vascular Biology

Background:

• Metformin demonstrates cardioprotective effects in ischemia reperfusion models, partly via nitric oxide (NO) synthesis.
• Investigated metformin's impact on random-pattern skin flap survival in rats.
• Explored the involvement of the NO system in metformin's effects.

Purpose of the Study:

• To evaluate the efficacy of metformin pretreatment in enhancing skin flap survival.
• To elucidate the role of the nitric oxide (NO) system in metformin's protective effects on skin flaps.

Main Methods:

• Rats received varying doses of metformin (150-300 mg/kg) 4 hours before skin flap elevation.
• Flap survival was assessed 7 days post-surgery; pathological review was conducted.
• Nitric oxide synthase inhibitor (L-NAME) and NO precursor (L-Arginine) were used to probe the NO pathway.

Main Results:

• Metformin doses of 200 and 300 mg/kg significantly increased skin flap survival.
• L-NAME administration negated metformin's protective effects, confirming NO dependency.
• L-Arginine enhanced metformin's effects, increasing flap survival and vasodilation.

Conclusions:

• Metformin pretreatment enhances random-pattern skin flap survival in a rat model.
• The protective mechanism of metformin in this context is dependent on the nitric oxide (NO) pathway.